Aileron posts Q1 net loss of $7.1M; positive Phase 1b data for LTI-03 in IPF

Rein Therapeutics, Inc.

2024-Q1 EPS reported -$0.86

Q1 net loss $7.1M ($0.86/share) vs $4.8M ($1.05) in Q1 2023; R&D expenses rose to $3.5M from $1.8M.
Cash $12.0M at March 31, 2024; after May 2024 $20M offering, expects to fund operations into H2 2025.
Positive Cohort 1 data for LTI-03 in IPF: statistically significant in 3 of 8 biomarkers; no SAEs reported.
Topline results from high-dose Cohort 2 expected Q3 2024; also Brian Windsor appointed President and CEO in March.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Rein Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter, EPS The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte.

Period: first quarter ended March 31, 2024
Net income: Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter
EPS: The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-139510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.